Decoy Therapeutics Inc. (DCOY) - Total Liabilities
Based on the latest financial reports, Decoy Therapeutics Inc. (DCOY) has total liabilities worth $4.55 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Decoy Therapeutics Inc. growing its equity to track the company's year-over-year net asset growth rate.
Decoy Therapeutics Inc. - Total Liabilities Trend (2014–2025)
This chart illustrates how Decoy Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Decoy Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Decoy Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UNITED OIL+GAS PLC LS-01
F:1UO
|
Germany | €1.89 Million |
|
Netmedia Group S.A.
PA:ALNMG
|
France | €19.40 Million |
|
Treatt PLC
LSE:TET
|
UK | GBX32.65 Million |
|
Literacy Capital PLC
LSE:BOOK
|
UK | GBX29.03 Million |
|
Shrenik Limited
NSE:SHRENIK
|
India | Rs1.82 Billion |
|
Brown Advisory US Smaller Companies PLC
LSE:BASC
|
UK | GBX1.55 Million |
|
Oryx International Growth Fund
LSE:OIG
|
UK | GBX1.06 Million |
|
iOThree Limited Ordinary Shares
NASDAQ:IOTR
|
USA | $4.88 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Decoy Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Decoy Therapeutics Inc..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Decoy Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Decoy Therapeutics Inc. (2014–2025)
The table below shows the annual total liabilities of Decoy Therapeutics Inc. from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.17 Million | +241.94% |
| 2024-12-31 | $1.51 Million | +16.32% |
| 2023-12-31 | $1.30 Million | -69.55% |
| 2022-12-31 | $4.27 Million | +102.10% |
| 2021-12-31 | $2.11 Million | -23.88% |
| 2020-12-31 | $2.77 Million | -16.31% |
| 2019-12-31 | $3.31 Million | +199.33% |
| 2018-12-31 | $1.11 Million | -81.20% |
| 2017-12-31 | $5.89 Million | +51.04% |
| 2016-12-31 | $3.90 Million | +35.45% |
| 2015-12-31 | $2.88 Million | -93.17% |
| 2014-12-31 | $42.15 Million | -- |
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverage… Read more